X4 Pharmaceuticals, Inc. (XFOR)

4.14 +0.09 (+2.22%) USD  |  NASDAQ  |  Aug 25, 14:13
More

X4 Pharmaceuticals Revenue Estimates for Next Quarter

Revenue Estimates for Next Quarter Chart

View Revenue Estimates for Next Quarter for XFOR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue Estimates for Next Quarter Chart
Start Trial

Historical Revenue Estimates for Next Quarter Data

View and export this data back to 2024. Start Trial.
Date Value
August 07, 2026 --
August 06, 2026 --
July 10, 2026 --
June 02, 2026 --
May 06, 2026 --
April 29, 2026 --
March 24, 2026 --
March 18, 2026 --
March 17, 2026 --
March 09, 2026 --
February 06, 2026 --
December 05, 2025 --
November 10, 2025 --
November 07, 2025 --
October 30, 2025 --
September 23, 2025 --
August 28, 2025 --
August 17, 2025 --
Date Value
August 13, 2025 --
August 12, 2025 --
June 16, 2025 --
June 10, 2025 --
May 02, 2025 --
May 01, 2025 --
March 27, 2025 --
March 26, 2025 --
March 25, 2025 --
February 07, 2025 --
November 14, 2024 --
November 13, 2024 --
August 09, 2024 --
August 08, 2024 --
May 07, 2024 --
April 30, 2024 --
April 29, 2024 --
April 03, 2024 --

Revenue Estimates for Next Quarter Range, Past 5 Years

View Revenue Estimates for Next Quarter Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue Estimates for Next Quarter Benchmarks

View Revenue Estimates for Next Quarter Benchmarks
Start Trial
Sarepta Therapeutics, Inc. Upgrade
Arrowhead Pharmaceuticals, Inc. Upgrade
Oncolytics Biotech, Inc. Upgrade
Sangamo Therapeutics, Inc. Upgrade
Anixa Biosciences, Inc. Upgrade

Revenue Estimates for Next Quarter Related Metrics

Revenue Estimates for Current Quarter Upgrade
Revenue Estimates for Current Fiscal Year Upgrade
Revenue Estimates for Next Fiscal Year Upgrade
EPS Estimates for Current Quarter Upgrade
EPS Estimates for Next Quarter Upgrade
EPS Estimates for Current Fiscal Year Upgrade
EPS Estimates for Next Fiscal Year Upgrade